Dry Age-Related Macular Degeneration Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023
DelveInsight’s, “Dry Age-Related Macular Degeneration Pipeline Insight 2023” report provides comprehensive insights about 58+ Dry Age-Related Macular Degeneration companies and 64+ pipeline drugs in the Dry Age-Related Macular Degeneration pipeline landscape. It covers the Dry Age-Related Macular Degeneration pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
- DelveInsight’s Dry Age-Related Macular Degeneration pipeline report depicts a robust space with 58+ active players working to develop 64+ pipeline therapies for Dry Age-Related Macular Degeneration treatment.
- The leading companies working in the Dry Age-Related Macular Degeneration market include Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
- Promising Dry Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
- On January 2023, Luxa Biotechnology Inc. announced a study of Phase 1 & 2 Clinical Trials for RPESC-RPE-4W. The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
- On August 2023, Smilebiotek Zhuhai Limited announced a study of Phase 2 Clinical Trials for QA102. This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes.
Request a sample and discover the recent advances in Dry Age-Related Macular Degeneration Treatment Drugs @ Dry Age-Related Macular Degeneration Pipeline Outlook Report
The Dry Age-Related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Age-Related Macular Degeneration drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Age-Related Macular Degeneration clinical trial landscape.
Dry Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons.
Find out more about Dry Age-Related Macular Degeneration Treatment Landscape @ Drugs for Dry Age-Related Macular Degeneration Treatment
Dry Age-Related Macular Degeneration Emerging Drugs Profile
- ALK-001: Alkeus Pharmaceuticals
- Elamipretide: Stealth BioTherapeutics
- CPCB-RPE1: Regenerative Patch Technologies
- AAV.sFH: Aevitas Therapeutics
Dry Age-Related Macular Degeneration Pipeline Therapeutics Assessment
There are approx. 55+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The Dry Age-Related Macular Degeneration companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.
Learn more about the emerging Dry Age-Related Macular Degeneration Pipeline Therapies @ Dry Age-Related Macular Degeneration Clinical Trials Assessment
Scope of the Dry Age-Related Macular Degeneration Pipeline Report
- Coverage- Global
- Dry Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Dry Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Dry Age-Related Macular Degeneration Companies- Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
- Dry Age-Related Macular Degeneration Pipeline Therapies- RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others.
Dive deep into rich insights for new drugs for Dry Age-Related Macular Degeneration Treatment, Visit @ Dry Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Dry Age-related Macular Degeneration: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Dry Age-related Macular Degeneration– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Abicipar pegol: Molecular Partners
- Late Stage Products (Phase III)
- ALK-001: Alkeus Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Elamipretide: Stealth BioTherapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- AAV.sFH: Aevitas Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Dry Age-related Macular Degeneration Key Companies
- Dry Age-related Macular Degeneration Key Products
- Dry Age-related Macular Degeneration- Unmet Needs
- Dry Age-related Macular Degeneration- Market Drivers and Barriers
- Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
- Dry Age-related Macular Degeneration Analyst Views
- Dry Age-related Macular Degeneration Key Companies
- Appendix
For further information on the Dry Age-Related Macular Degeneration Pipeline therapeutics, reach out to Dry Age-Related Macular Degeneration Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market
